TitleCancer Therapeutic with Increased Efficacy and Reduced Side Effects
OwnerUniversity of Florida
Dislike
0
Description

Uses Small Drug-Like Molecules to Prevent Cancer Cell Proliferation

This breakthrough approach to treating cancer is efficacious and has limited side effects. Cancer is a leading cause of death in the United States, accounting for one in four deaths annually, according to the American Cancer Society. An estimated 595,600 Americans will die of cancer-related causes in 2016, and predictions for the future continue to rise. Existing treatments often suffer from a lack of efficacy or lead to debilitating side effects for the patient. Researchers at the University of Florida have developed a distinct therapy to specifically target cancerous cell proliferation and halt the growth of tumors and the spread of cancer. This breakthrough treatment also has minimal side effects, making it a desirable treatment for both the patient and health practitioner.

Application

A therapeutic cancer treatment that inhibits the proliferation of cancer

Advantages

  • Capable of preventing and treating cancer and other cell proliferation diseases, offering a therapy that is effective at a lower concentrations
  • Decreases cancerous cell proliferation, inhibiting the spread of cancer to other sites and improving the probability of life expectancy
  • Minimal side effects, improving patient quality of life and providing a significant market advantage

Technology

This technology is a specially designed therapeutic that treats and prevents cell proliferation diseases such as cancer. Small drug-like molecules are used to bind the dichloroacetate (DCA) binding pocket of pyruvate dehydrogenase kinase isoform 2 (PDK2) and inhibit cancer cell proliferation. A patient suffering from or susceptible to a PDK2 mediated disorder or disease is administered a therapeutically effective amount of a compound that activates PDK2 activity, thereby receiving treatment.

Date:08-20-2012
Applicants:University of Florida
Access to additional documentation:Please inquire
Case Ref:12854
Application number:USPending
Inventors:David A. Ostrov, Peter W. Stacpoole, Arun Srivastava,
Support from inventors:Please inquire
Industry:Healthcare
Meta information:
Meta title:
Publication number:
Priority number:
Please fill out the form and press 'send'
Contact Seller
Please provide your contact information below.

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Image CAPTCHA
Use this form to contact the IP-owner - you should provide an email of your choice for contact. Indicate your interest/reason for the contact.
Disclaimer: Licentix do not guarantee that message sent using this form will be read by the recipient. Please contact us if you are not recieving any response.